The investigational, novel, injected once-weekly “twincretin” tirzepatide met its primary efficacy endpoint of significantly cutting hemoglobin A1c as well as its secondary weight-loss endpoint in patients with type 2 diabetes when compared with control patients in top-line results from each of five discrete pivotal trials. The company developing tirzepatide, Lilly, announced these results in a
Being obese and pregnant raises the risk for cardiac complications in women with preexisting heart disease, new research suggests, highlighting the need for earlier interventions in this high-risk population. The analysis of 790 pregnancies revealed that 23% of women with obesity, defined as body mass index greater than 30 kg/m2, had a cardiac event
A 2.4-mg weekly injection of the glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide led to a clinically meaningful 5% loss in weight for roughly two thirds of patients with both overweight/obesity and type 2 diabetes, researchers report. These findings from the Semaglutide Treatment Effect in People With Obesity 2 (STEP 2) trial, one of four phase
Obesity researchers from around Missouri, led by scientists at Washington University School of Medicine in St. Louis, have received a grant to help evaluate and put in place family-focused weight-management programs designed to reduce childhood obesity, particularly among children from low-income families. With a five-year, $3.7 million grant from the Centers for Disease Control and